SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 92.3% in October

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the recipient of a significant growth in short interest in October. As of October 15th, there was short interest totalling 79,800 shares, a growth of 92.3% from the September 30th total of 41,500 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average trading volume of 49,400 shares, the short-interest ratio is currently 1.6 days.

Institutional Trading of SAB Biotherapeutics

An institutional investor recently bought a new position in SAB Biotherapeutics stock. First PREMIER Bank purchased a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 19,386 shares of the company’s stock, valued at approximately $60,000. First PREMIER Bank owned 0.21% of SAB Biotherapeutics at the end of the most recent quarter. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Price Performance

SABS stock traded up $0.08 during midday trading on Friday, reaching $2.77. The company had a trading volume of 20,531 shares, compared to its average volume of 26,467. The stock has a 50 day moving average price of $2.76 and a 200 day moving average price of $3.07. SAB Biotherapeutics has a fifty-two week low of $2.16 and a fifty-two week high of $10.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.24 and a current ratio of 5.24.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.34. The firm had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative return on equity of 94.04% and a negative net margin of 1,450.14%. On average, equities analysts predict that SAB Biotherapeutics will post -3.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on SABS. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a report on Monday, August 12th. Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, September 9th. Oppenheimer reiterated an “outperform” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a research report on Thursday, September 12th. Finally, Craig Hallum started coverage on SAB Biotherapeutics in a research report on Wednesday, October 9th. They set a “buy” rating and a $11.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, SAB Biotherapeutics currently has a consensus rating of “Buy” and a consensus target price of $12.40.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.